Submission for Life Science Award - Bio-IT World 2018

Brief description of problem addressed by product (250)

Sapientia enables faster diagnoses and raises diagnostic yields for patients suffering from monogenic rare diseases.

There are more than half a billion people living with a rare disease. Seven percent of the world’s population. Eighty percent of their diseases have a genetic component, some with only one mutation amongst 3.2 billion nucleotides. These may be inherited, or be de-novo mutations and others may be mutations so rare that they have never been seen before.

The unfortunate fact is that rare disease is not that rare and 95% of these diseases have no treatment available and tragically, most rare disease patients won’t reach their fifth birthday.

Whole genome and whole exome sequencing, tantalisingly, offers humanity’s best chance to take the initiative in the battle against disease and it was this opportunity that galvanised five of the world’s leading geneticists to found Congenica and develop Sapientia.

Spun out of the pioneering Deciphering Developmental Disorders (DDD) research project at the Sanger Institute, Sapientia provides variant calling pipelines and an interpretation interface that enables identification of causal variants and gives users the power to bring the average diagnostic odyssey down from 7.3 clinicians over 4.8 years to just 1 clinician and 5 days.

In addition to the reduction in clinical costs, this rapid diagnosis provides some peace of mind for the affected individual and their family, which also enabling treatment plans to be implemented at the earliest possible opportunity.

Brief product description & technical specifications (250)

Sapientia integrates a suite of powerful analytical tools, enabling rapid, accurate and scalable interpretation of a patient’s whole genome, whole exome or gene panel data facilitating a swift, actionable and comprehensive diagnosis.

Central to Sapientia is the fully integrated Genome Browser, which allows customers to thoroughly interrogate and visualise the patient’s variants. It includes a karyogram display to navigate chromosomes, alongside SNPs, small insertions and deletions, CNVs and larger structural variants.

The system integrates leading tools such as Exomiser, which allows users to prioritise variants according to their relevance to patients’ phenotypes whilst filtering out common and synonymous variants. It leverages reference databases including ClinVAR and DECIPHER, unified alongside Congenica’s own internal knowledgebase of HPO annotated variants curated by clinical experts through routine use of the platform, and users’ own databases.

Powerful bioinformatics pipelines underpin these systems and are developed by Congenica’s world-class bioinformaticians. Clinical diagnoses and reports are signed-off by a team of leading registered clinical scientists. The easily scalable, secure and ISO certified cloud based platform of Sapientia allows for effortless asynchronous multi-disciplinary meetings with complete confidence.

Sapientia is easy to adapt and consolidate into a wide range of instantly scalable workflows; from a lab deeply interrogating an individual sample or labs processing population wide studies. Congenica has proven this through our role as an official interpretation partner for the UK 100K Genomes Project.

Sapientia enables clinicians to interpret a patient’s genome in as little as 30 minutes, empowering doctors and clinicians to diagnose the previously undiagnosable.

Brief description of innovative technology (250)

Sapientia facilitates rapid, accurate diagnosis of rare diseases by integrating a suite of ‘best in class’ analytical tools in an intuitive User Interface. Comprehensive diagnosis is simplified by enabling users to view and interpret patients’ genotypic and phenotypic data while delivering supporting information via the Sapientia knowledgebase.

Sapientia presents whole genome, exome or gene panel data in a single integrated platform. This allows for quick and easy interrogation and annotation of genes and their pathogenicity using HPO terms, and supported by an ever expanding knowledge base drawn from gold-standard variant databases and academic publications.

Furthermore, Sapientia provides clinicians with a secure, ISO certified platform to share their diagnoses and discoveries for mutual benefit. Users are able to connect with other organisations to see if their patient’s variant has been seen before and with those that have diagnosed similar cases in the past.

These decisions and diagnoses provide valuable peace of mind, closure and reproductive knowledge to the families of patients avoiding an arduous and dehumanising diagnostic odyssey.

By using Sapientia, the Manchester Centre for Genomic Medicine (MCGM), UK, has been able to scale up the genetic testing in its ophthalmology department from undertaking single gene sequencing for 10 - 15% of patients to being able to offer gene panels of up to 170 genes to 100% of patients.

Congenica’s platform is also deployed at St.George's University Hospital in Tooting, southwest London. Here, Sapientia was used to reach clinical diagnoses in just 3 weeks, an impressive 13 weeks earlier than through traditional methods.

Life Science Marketing Personas for sales support

Title: Clinical Scientist

Role: Influencer

Demographics & Titles:

  • Age range spans whole working life as there is excellent room for job progression and specialisation.

  • Gender split is approx. 60-40 to female. University grads in recent years follow this trend so gap will widen further.

  • ‘Clinical Scientist’ is a protected title and requires very extensive training and expertise to achieve. The title may only exist in the UK but other regions have their own analogues, Medical Scientist in the US for example. China has no equivalent and only 2 uni’s in the whole country capable of training people to a relative standard.

  • Usually live in big cities with major hospitals or life science sectors. Often work in hospitals which mixes friends, peers etc. into one group.

  • Pay range is large, from £25k for recent graduates to £100k+ for experienced, specialist FRCPath level positions though highest wages are in Pharma.

  • However, NHS work is attractive to these people as it offers stability with good benefits, pension & maternity packages. Also maintains altruistic ideals.

Values & Goals:

  • They value their work and role in the wider infrastructure that underpins the delivery of any modern healthcare system very highly. “Even on the worst day at work I still know I’ve made a difference.”

  • These values come from a sense of deciding a patient’s whole future. Genetic testing is one-off, if they say ‘all clear’ or make a mistake, no-one is getting retested.

  • They appreciate methods and protocols being in place and followed because they value their professionalism and reputation.

  • The ultimate goal of everything they do is to help patients. Factors such as raising diagnostic yield or deploying new technology need to be justified and validated by this first and foremost. They do embrace tech though based on evidence.

  • They value their professional reputations, and that of their labs, extremely highly hence their appreciation of methods, protocols and their adherence to them. They prize good, clear science that helps people. They carry these macro goals with them.

  • Surveys show a decent level of job satisfaction (68%) and a high level of job meaningfulness (83%). Many talk of personal or familial contact with disease or conditions which motivates them. These are commonly Alzheimer's and cancer.

  • Most Lab Directors used to be Clinical Scientists, hence they are respected and listened to.

Average Day:

  • Have regular routines, however, considerable deviation between different CS’s routines depend on the nature and location of services being delivered.

  • Work with complicated equipment regularly and confidently, commonly communicating with colleagues by telephone, email and fax but extremely rare for them to see patients. “I get to help people without having to see them.”

  • If they are not doing lab work they are looking at a computer screen

  • Commonly involved in MDT’s

  • Interpret and evaluate data and write and authorise clinical reports.

  • Work with realia everyday which underpins their ‘real-world’ outlook.

  • Undertake daily monitoring of audits, health and safety and quality protocols.

Common Objections & Obstacles:

  • We don’t have budget

  • We have our own solution/pipeline/platform in place

  • We are using X product and don’t want the cost and time to validate and implement.

  • We don’t like black boxes

  • We don’t trust cloud based solutions

  • It's not as comprehensive as they’d like, eg . missing CNV’s.

  • “I have patients to care for, I don’t have time for this.”

Challenges and Pain Points/problems:

  • Staff spread too thin. Recruitment freezes. Not enough bodies.

  • They are almost constantly under financial pressure in; “a system which doesn’t understand spend to save.”

  • Needs reliable, accurate diagnoses as swiftly as possible

  • Does a lot of repetitive and time consuming tasks

  • Push for less qualified staff to do legwork, risk of deskilling.

  • Has a distrust of new technology and buzzwords, wants results, proof and source.

  • Spending money on a better and more efficient clinical decision support solution such a Sapientia may save the health service as a whole a lot of money (e.g. less tests, less stays in hospital etc etc), but the budget for Sapientia would come from the Regional Genetics Lab, and the savings would be realised in someone else's budget.

Biggest Fears:

  • Lab makes mistakes which puts patients/projects at risk and harms reputation of lab and those who work there.

  • Reconfiguration of NHS labs (21 down to 6) there will be job losses, downsizing. Unknown as to how they would react. May face pay cuts.

  • Maintaining quality, balancing benchside and budget

  • That something happens which affects the patient

Experience she/he wants:

  • A streamlined system which makes their working lives more efficient

  • To be assured in the accuracy of the process and reliability of its results

  • To be able to hand-off repetitive or tedious tasks and have more time for complex or interesting problems.

  • He/She has chosen to stay in this role and specialise rather than entering admin/management roles and thus they want to keep doing ‘science’ not paperwork.

  • To maintain a highly respected professional voice.

  • Solutions which prize function over form, are validated and can be used with confidence.

  • More value for the average patient and more insight and time to work on the more complex cases

  • A solution that allows historic cases to be reanalysed as our knowledge improves over time (e.g. a VUS is upgraded, so earlier cases that didn't originally receive a diagnosis, might now be diagnosable).

Info Sources:

  • They prize scientific journals the highest, then the niche press, popular science, industry forums and chat rooms and lastly the mainstream media.

  • OMIM

  • PubMed

  • Nature Genetics

  • American Journal of Human Genetics

  • GenomeWeb

  • Twitter

  • Conference coverage

  • Various scientific journals

  • Individuals’ blog

  • [It is important to recognise that they often consume a lot of information throughout their working day and hence don’t often read about work related matters outside often preferring escapism.]

Title: Lab Director

Role: Decision Maker

Demographics & Titles:

  • Salary: High enough to not be listed - over £100k

  • A1’s/A2’s

  • They are highly paid and respected

  • May be driving force behind project choices, may be selecting them on personal influence or due to past study or research experience

  • People in these jobs tend to have had connections to the labs, institutes or colleagues with whom they work.

  • The money motivated gravitate to pharma, the project orientated tend to gravitate towards academia in the US and research institutes in the UK.

Values & Goals:

  • “Lead, grow and enhance research function of the business”

  • Detail oriented

  • Needs to provide value

  • Need to provide improvements/streamlining

  • There is quite high job satisfaction (75%)

  • Decent sense of job being meaningful (62%)

  • Methodical, systematic mind required to keep many factors in play at one time

  • They like to know the processes of things, black boxes are not going to meet their criteria.

  • They manage a lot of potentialities and have done throughout their careers. They are solution and workflow focused.

  • They value their time and effort. Streamlining has value to them.

  • They value oversight. Security and audit trails have value to them.

  • They are communicators, they have to liaise with many parties, they have to present data, write papers, pitch/critique projects. They are good active listeners and strong authoritative speakers.

  • Professional integrity underpins their reputation and attention to detail and compliance to protocol underpin this sense of integrity.

  • They must be flexible and adaptive throughout the projects etc.

  • They are committed to their work, maybe because they have the personal investments in their projects or teams, however this often leads to long working hours and they commonly take their work home - if not physically then in their minds.

  • They are persuaders, advocates - even devil’s advocates - they may be required to take risks or leaps of faith in their work but do so with a lot of due diligence.

Average Day:

  • “Lead, grow and enhance research function of the business”

  • Usually reports directly to C-levels

  • Work hand in hand with Principal Scientist/Investigator

  • Manages target lists

  • Plan, direct and coordinate the projects.

  • Ensure compliance

  • Must maintain records and compliance, including consent.

  • May also undertake testing etc themselves as they still like to ‘get their hands dirty’.

Common Objections & Obstacles:

  • There’s no budget

  • There’s no contingency

  • There’s no free lab staff

  • There’s no time for training

  • There are established protocols in place

  • There’s no need to rock the boat

Challenges and Pain Points/problems:

  • Find themselves caught up in an ‘executive’ life of meetings and titles and paperwork but may still be a scientist at heart.

  • There is a tacit understanding that spending should be ‘streamlined’, regardless of that, they will always be resistant to spending any money.

  • At the same time they are also under pressure to provide some tangible improvements during their time.

  • They have worked hard to get where they are and don’t want to risk anything by rocking the boat and doing something new.

  • GDPR

Biggest Fears:

  • There is low job growth and quite slow progression, some may feel trapped in their current role.

  • That they will not be able to fulfil their goals due to outside influence from the administrative or commercial sides of their businesses.

  • Mistakes or scandals coming out of their labs

  • Getting replaced due to underperformance

  • Getting replaced due to internal politics

  • That one of the various plates they have spinning will fall and break

Experience she/he wants:

  • They feel that they are the ‘bigwigs’ of the lab and research environment. They may not have the corner office and the cliched trappings of success but feel entitled to it.

  • Wants to drive their own lab. Would really like all of the red tape gone and to have the freedom of when they were scientists but with the agency they have now.

  • To be respected and listened to.

  • To put science, method and quality first.

  • To be able to make breakthroughs, write papers and raise profile.

  • To cure or treat something previously impossible.

Info Sources:

  • [Of the three personas this was one of the more difficult things to drill down into as they don’t seem to do this as visibly as the others investigated under this piece of work]

  • The most common sources of information are the top scientific and medical journals, eg: PubMed, Nature, NCIB .

  • They also gather information from within the niche press.

  • They are big sharers of articles and information and get a lot of leads and pointers on what to read from their peers.

  • They promote and share their publications, those of others in their institutions and their peers.

  • They are proactive networkers and attend a lot of meetings and conferences which empowers this as a proactive information source.

  • They will follow the work of big names and big institutions in which they are interested or who are parallel or relevant to their lab’s work.

  • Twitter

  • Citations from their own or peers works.

  • Arma

Title: Bioinformatician [NB – People consistently talk about a generational split in bioinformatics that happened around 2010 before which people would have studied an ‘ology’ before going into bioinformatics whereas afterwards people studied bioinformatics as its own thing.]

Role: Influencer

Demographics & Titles:

- Very highly sought after with seniority and experience on active projects outweighing administrative or managerial experience.

- Have value in their own right. One of the most saleable things about Congenica is that we have gathered a large group of talented bioinformaticians and data scientists in one place with overlapping skills and expertise; this is also attractive to them as they like to learn from analogue peers.

- Very highly skilled, need biology, maths and computer science

- Qualifications push them up ABC rankings

- Salaries from around £30k - £50k

- Working hours can be long and demanding especially in research and start-ups.

- Has wider applications outside of healthcare

- Becoming one is very very hard, due to skill range required and need to be seen to have ‘flair’ or ‘own way’. Computational yet creative.

- Job growth and progression is described by peers and industry publications as ‘bad’ due to limited field or options and a view that entering management takes you away from ‘the coal face’

- Need a number of qualifications or experience on a number of projects

- Industry sources disagree whether there is career growth

- Vastly male.

Values & Goals:

- They recommend technology based solutions for research or determine computational strategies.

- Desire stability.

- Very technical when you get into what they do

- Surveys show fairly high job satisfaction (69%), in areas such as Cambridge this could be even higher as being in demand gives them significant ‘buying power’ when job hunting.

- Need to be an active listener and a consultative problem solver with strong critical thinking and organisational skills and a person who likes to learn from doing.

- Need to have a personality with persistence, integrity and dependability. Doing the job ‘properly’ and ‘respecting the data’ are very important.

- A moderate sense of the job being meaningful (65%). Research will be lower, start-ups about this level but would be higher in established and targeted company.

- Undertake personal projects throughout their with hardware, software, programming etc.

- Raspberry Pi ownership is very high and they have an element of ‘dev-ops’ in their thinking.

- They inform management and higher research types to empower them to make better strategic decisions. Given the volume of data they are often seen as having highly valuable insight unattainable outside.

- Need patience and perseverance

- See themselves as ‘at the coal face’ or ‘in the trenches’ of the business, “essentially bringing the scientists from A to B or C or Z”.

Average Day:

- Always on a computer or in a meeting

- Code, process, analyse, review, debug, test, iterate, review, repeat.

- Integrate open source, in house or proprietary databases

- Work extensively with clinical, devs/engineers and dev ops.

- Develop novel software applications and pipelines to meet specific project requirements

- Working hours can be long and demanding

- Are often called upon to communicate research through conference presentations, publications etc.

- Deal with ideas and concepts that require sustained thinking hence it can be hard for them to ‘switch off’ after work.

- The work can tend to be procedural (implement, test, fix), reactive (bugfix, firefight) and creative (troubleshooting).

- In research settings they assess discordance between compressed and uncompressed NGS data. “The volume of data is becoming more critical which is creating new tasks around storage, back-ups, compression etc.”

- In service setting they provide; quality control , maintenance and improvements, pipeline assembly, archiving of annotated sequences. “You feel a shift in companies as they get closer to commercialisation.”

- “Best part is you never have to do overnight timepoints, no one is dying is bioinformaticians don’t come to work at the weekend.”

- Linux and Unix users

- May use Python, R, Perl, C++, Java.

- Work to tight deadlines

Common Objections & Obstacles:

- Will probably claim to have or to be able to do anything we have already.

- Bioinformaticians talking to bioinformaticians about bioinformatics can be really negative.

- Not a very mature field, some people may not be as skilled or knowledgeable as you might expect.

- Concerned about disruption to their data flow and ongoing projects.

- Worried that they may spend time fixing and troubleshooting Sap.

- They already often have to justify the tools and systems they are using, this can make them skeptical of new things or even jaded by being pitched ‘solution’ after ‘solution’.

Challenges and Pain Points/problems:

- Managers without clear grasp of the science often have unrealistic expectations.

- Sometimes feel they are asked to do too much with too little.

- Bosses or project heads often want ‘sexy’ results without realising all the hard work that happens behind them.

- Field of study/science is based upon trying to find definitive meaning but you have so little information and the error-rate is so high.

- Sometimes feel like they are “caught in the middle” of two side of the business and being asked to “swim upstream”.

- Often get vague or unreasonable briefs from higher ups who don’t understand what they do

- Under pressure to keep abreast of technology,

- Are required to improvise quite often, sometimes from scratch.

- The biggest problems they face are often linked to management, unrealistic goals and ‘legacy code’

Biggest Fears:

- Something will come along and make their pipelines, code and technology redundant.

- The open source tools they rely on will become closed source and other protectionist policies.

- What will are the other companies doing? Will we get left behind?

- Will I/the team/the company be able to keep pace with the competition or changes in methodology and implementation?

- You have to invest a lot of personal time into keeping yourself informed an up to date, this can build insecurity.

- The company needs to listen to and invest in its team, if this isn’t happening the fears around being left behind etc. are increased in relation to it.

- There is a trade off between maintaining what you have, management how it works, planning for the future and implementing improvements. This is a complex process that can have far reaching consequences if not done well.

- Unexpected errors which go undetected and effect results generated by their pipelines.

- People either trying to reinvent the wheel or asking them to reinvent the wheel.

Experience he/she wants:

- Fewer ‘dev-ops’ type tasks

- Integrated workflows, especially with clinical teams

- Their skills can sometimes feel like a ‘double edged sword’ to them, they would like more time on interesting and creative projects and less time on the procedural and repetitive tasks.

- To have full confidence in the results being accurate and stable.

- To be respected for their work and not feel like ‘code monkies’.

- To work in a close knit and collaborative team

- To be part of interesting projects

- To have a voice within their team and company

- To have the freedom to try new things

Info Sources:

  • [There is a lot of personal interaction spoken about and peer to peer knowledge sharing through events, meet-ups and forums plays a much larger role than the other personas]

  • They often crowdsource answers and support from their peers on sites like StackOverflow

  • Biostat

  • Attending inter-team meetings and team building exercises.

  • Maintaining a good physical and virtual network

  • Other dev’s and bioinformatician’s blogs

  • Digital Ocean

  • Internal documentation

  • Github

  • ReadtheDocs

  • Mozilla Developer Network (mostly Java)

Congenica - COO's end of year newsletter

It's been an exciting year here at Congenica. We have welcomed new appointments both in the UK and across our ever expanding network of international satellite offices, new clients in new territories and new enhancements and refinements of our platform, Sapientia.

Following a successful Series B funding in February, Congenica have been able to continue spreading our wings. It's very exciting to have overseen the opening of our first overseas offices on the American coasts, Philadelphia, PA, and San Diego, CA. The two cities and their regions share a lot of the characteristics that we prize about our home city of Cambridge, as they boast vibrant life sciences sectors, world leading academic institutions and dynamic venture capital atmospheres.

We have entered into a partnership with the Beijing Genomics Institute (BGI) who are one of the world’s largest DNA sequencers. China is an exciting opportunity for genomics with a large population and need to modernise the healthcare infrastructure combining to make personalised medicine not just possible but preferable as the task they face is orders of magnitude bigger than in any other country. BGI’s work and our partnership with them are exciting parts of everything which is happening and of capitalising on the bounty of genomic data being generated.

Sapientia is specifically how we help them do that by, simply, putting more clinically actionable data in front of the doctors faster and more accurately than anyone else on the market. The latest release represents a significant milestone, with better ClinVar integration and streamlined gene panel management tools, American Council of Medical Genetics and Genomics (ACMG) guidelines and a focus on system performance and resilience to drive improvements for all users. Sapientia was nominated at Bio-It World for the Best Practices and Best in Show awards for their innovative use in Thrombogenomics.

As great as these things are, Congenica is much more than just the company and the product. We have deepened our support of patients with struggling with rare disease and their families and carers by working with publication and community Rare Revolution. Nicola Miller and Rebecca Stewart, who operate the and publish the magazine, have launched a new magazine which is run and written by and for children and young people with rare diseases and we are proud to be mentoring some of their young writers.

We have enjoyed attending a number of industry events this year but particular highlights would have to be ESHG and ASHG. The latter was especially good as we held a symposium on impacting clinical diagnostics using rapid and accurate whole exome analysis in which we were delighted to be joined by; Dr. Avinash Abhyankar of the New York Genome Center, Nathalie Chandler of G.O.S.H. and Dr. Yuan Yuan Fu of Fuwai Hospital, experts from around the world mirroring the global expansion of us as a company.

Next year will be even more exciting though as we already have a webinar alongside the amazing Jill Viles lined up for February.

Our Scientific Director, Dr. Matt Hurles, received two very prestigious appointments. The first was his election to the Academy of Medical Sciences which is an independent UK body that promotes and supports medical research. The second was his appointment as the head of the Human Genetics Programme at the Wellcome Trust Sanger Institute, a department he first joined in 2003.

Additionally, Laura Taylor, ACA, our Chief Financial Officer was named as one of the top 50 female leaders in UK life sciences when she was nominated for BioBeat’s, Movers and Shakers in BioBusiness Awards for the second year running.

It's been a great year for Congenica and for the industry as a whole and I’m really proud of the dedicated team in and around Congenica and Sapientia who are making this all happen.

Rare Disease Diagnosis: A Patient’s Perspective

Rare disease, by definition, is sporadic, and information on it is sparse; but with over 7000 rare diseases currently classified worldwide, 1 in 17 people will suffer from a rare diseases at some point in their lifetime, and ‘rare’ does not seem like the right term any more. Tragically, 30% of those affected by a rare disease will not see their fifth birthday, and 95% of the disorders known today have no drug treatment available at all.

Three years ago, six of the country's leading geneticists began ground-breaking research into rare diseases at the Wellcome Trust Sanger Institute in Cambridge. The project was called Deciphering Developmental Disorders (DDD) and it analysed genetic data for conditions so rare that, in some cases, they had never been seen before.

Using what they learned from their research, some of those geneticists went on to create a software programme: Sapientia, which could analyse the genetic data of patients with a rare disease. Like the DDD project before, their focus was looking at the whole scope of a patient’s genome. Instead of looking at snippets of the genome for a single disorder, they wanted to look at all of the information within the whole genome to gain a better understanding of what caused rare diseases.

Sapientia’s creators understood that a diagnosis could have as big an impact on the psychology of the patients, their families and their carers as treatment could have on the condition itself. Diagnoses are more than just clinical tools, they give all involved the certainty that they may have been lacking. It allows patients to get access to the right treatments at the right time, and allows the family clarity on the potential status of future children. A diagnosis can also give a patient access to clinical trials, patient groups, disability allowance, and a community of affected people. Above all else, a diagnosis gives their struggle a name.

 

Founders

Three years ago six of the world’s leading geneticists came together to found a company focused on revolutionising how rare diseases are identified, catalogued, treated and ultimately, where possible, cured. The had each been carrying out research in their own fields and in their own institutions but found themselves kindred spirits due to that core driving factor underpinning it all, the task of tackling the rarest diseases.

Their idea centred around a clinical analytics platform capable of supporting, scientists, clinicians and researchers such as themselves through the various pitfalls associated with identifying, curating and interpreting genetic variants behind innumerable rare conditions. Conditions such as cystic fibrosis, sickle cell disease or congenital hyperthyroidism which in some cases may only be found in a single individual or family.

Key to the group was Dr Richard Durbin, now Group Leader in the Human genetics program at the Wellcome Trust Sanger Institute, who was himself a pioneer in the field of human genetics being personally involved, as he was, in developing sequence data analysis tools that are now industry standards. Richard has held some of the most prominent jobs in the field and has headed a number of ground-breaking and significant projects including the seminal 1000 Genomes Project and the UK10K Genome Project.

As the group shared ideas, experiences and aspirations they sought to clarify the vision of medicine which they shared. Rare disease is, by its very definition, sporadic and information on it sparse but certain statistics caught the attention of Richard and the other founders. Firstly, 1 in 17 people will suffer from a rare disease and 80% of these diseases were genetic in origin. The picture was becoming clearer. Secondly and crucially, it took on average five years, innumerable tests and multiple clinicians and doctors to reach an accurate diagnosis yet, tragically, 30% of children with a rare disease would not see their fifth birthday. Here, they could save lives. They could utilise their expertise. They could drive forward all of medicine.

Richard would become Informatics Director and was joined by Dr. Matthew Hurles, Science Director, now Senior Group Leader at Wellcome Trust Sanger Institute who himself had pioneered analysis of whole exomes in clinically relevant disorders that previously failed diagnostic methods. Dr. Philip Beals, Medical Director, who pioneered use of next generation sequencing in pathogenesis and ciliopathies. Dr. Nick Lench, Chief Operating Officer who, as the director of the North East Thames Regional Genetics service at Great Ormond Street Hospital for Children, had responsibility for 4.5 million people. Dr. Andy Richards brought his years of entrepreneurial experience to bear as Chairman. Dr. Tom Weaver, Chief Executive Officer, who brought with him extensive knowledge and experience with start-ups and applying genomic analysis and contract service based business models to new and innovative commercial ideas.

So, it was with this handful of minds, alongside nothing but their own determination and drive that Congeinca was born in a portacabin on the site of the Wellcome Trust Genome Campus in Cambridge, England.

In just four short months their ideas were creating enough buzz to see them given an exclusive Wellcome Trust commercial license. Work was taking place in earnest behind the flimsy walls of their humble home to bring their cutting edge ideas to life.

Six months later, Sapientia launched. Things were changing for people around the country and the world who struggle with rare disease, even though they didn’t know it yet.

The splash that Sapientia and Congenica made was big enough to draw some really significant attention and they were selected in the summer of 2015 as clinical interpretation partner for the ground-breaking and now oft-copied 100K Genomes Project by Genomics England.

Sapientia was a huge success at a time when the cost of sequencing was dropping dramatically and the wider medical applications and commercial opportunities which had always been on the minds of the start-up six were drawing into ever sharper focus.

This success and the innovative new applications, improvements and modifications which they were making saw the product and the company win a number of awards the following year. Congenica won the OBN Award for best implementation of digital healthcare whilst Sapientia was awarded the NHS innovation challenge. Those behind these startling achievements were also receiving their required recognition.

That summer also brought the realisation that growth and success was to force them out of their portacabins and the company saw itself move into the prominent Bioinformatics Centre at the Hinxton WTGC site and with it come waves of new staff and funding.

As 2017 dawned so did another new step for Congenica as the company spread its wings and proved its international credentials making its first strategic appointments in the US and seeing Sapientia in use in hospitals and labs around the world. They would go on to achieve their Series B funding and spread even further into the enormous market that is China with both investments and partnerships from the Asian powerhouse.

Now, respected for their vision, revered for their expertise and rewarded for their successes those bold founding few have built a leading company and paved the way for entirely new modes of medicines which have saved and changed lives around the globe already for those suffering rare disease and those supporting them.

Congenica crosses oceans and celebrates international expansion.

 

Cambridge based Congenica, who developed the gold standard genome analytics platform Sapientia, have now opened offices and created new partnerships across three continents; Asia, Europe and the Americas.

Congenica, which was only established in 2014, saw its series B funding completed in April of this year with investment from Chinese genomics giant the Beijing Genomics Institute (BGI) who are the one of the world’s largest DNA sequencing providers.

“Genetic analytics software will be a central part of China’s evolving healthcare system in the coming years. We are delighted to be at the forefront of this change and committed to the benefits it will bring to patients.” Said Congenica’s Chief Business Officer, Shikha O’Brien.

Another of Congenica’s partnerships is in supporting China’s 100K Wellness Pioneer Project, designed to gather 100,000 full genomes from Chinese individuals, both as a healthcare tool, and to aid in diversifying global genomic knowledge, which has previously been focused on genomes that are of European origin or descent.

The Chinese investors and partners have also signed up to use Congenica’s proprietary enterprise software Sapientia, which was used extensively by Genomics England on the 100K genomes project, meaning Congenica are in a position of rarefied experience to aid in this task.

“The unrivalled, integrated, end to end solution provided by the Sapientia software offers multiple advantages.” Said, Li Ning, Chief Development Officer at BGI.

Congenica have also seen new offices opening in California and Delaware in the U.S. where the company is enjoying increasing success and market penetration.

Closer to home the company have struck a deal with Portugal’s Coimbra Paediatric Hospital (CPH) where Sapientia will perform whole exome sequencing for the In2Genome project, which aims to revolutionize the diagnosis of rare genetic diseases through population wide genomic data.

“This additional investment, these new contracts and our new locations are all part of our international ambitions and they enhance our ability to deploy Sapientia to markets where we are establishing scalable partnership models to transform genetic testing.” Said Tom Weaver, CEO of Congenica.

 

Congenica’s Sapientia™ selected by Coimbra Paediatric Hospital for Portugal’s In2Genome Genetic Disease Diagnosis Project

Hospital-Padiatrico.jpg

Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Paediatric Hospital (CPH), a leading paediatric hospital in Portugal and part of the Coimbra Hospital and University Centre (CHUC). Through this partnership, the hospital has licensed Congenica’s Sapientia™ software platform to perform analysis of whole-exome sequencing data and produce diagnostic reports for its In2Genome project. The €1.2 million ( $1.4 million) project funded by Portugal2020, Compete 2020, and European Structural and Investment aims to revolutionize the diagnosis of rare genetic diseases through insights gained from population-wide genomic data.

Initiated by The Medical Genetics Unit of CHUC, which is housed in CPH, the In2Genome project is a multidisciplinary consortium collaborating with Portuguese companies Coimbra Genomics and Genoinseq by Biocant. The project, which commenced in July 2017, is expected to run for two years.

Sérgio B. Sousa, MD, PhD, Medical Geneticist at CPH, said: “This is a unique and innovative project for the Portuguese national health system. We have chosen Sapientia due to its already proven speed and high accuracy in other projects like the UK 100K Genomes Project. One of the main aims of In2Genome will be to set up a whole-exome sequencing analysis service at our leading public hospital centre. Our first project is the the study of a large cohort of patients with neurodevelopmental disorders, namely intellectual disability syndromes with the aim of developing faster precise diagnostics to better support patient’s health and lifestyle outcomes.”
 

Sapientia is currently deployed at a number of clinical and research organizations as well as being used for the interpretation of rare disease in the 100,000 Genomes Project. As an end-to-end solution, the platform is designed to allow clinicians to upload data in a number of different formats, using existing bioinformatics pipelines or adopting publicly available ones, and then to filter and interpret the genetic variants associated with disease.
 

Shikha O’Brien, Congenica’s Chief Business Officer stated: “Building on our global footprint, we are delighted to be working with CPH and CHUC, and to be part of an important national project in Portugal. The use of Sapientia in this clinical setting demonstrates the value of the platform, especially in diagnoses of paediatrics cases where speed and accuracy is of utmost importance.”
 

Professor Jorge Saraiva, Director of both CHUC’s Medical Genetics Unit and CPH, added: “This project is strategically important to us and an important milestone in clinical genetics. It was critical that we selected the best, and clinically most experienced, partners to ensure success. Congenica has gained a significant depth of know-how from its work with the UK NHS and Genomics England, which provides valuable experience to draw upon.”
 

About Coimbra Paediatric Hospital and Coimbra Hospital and University Centre

Coimbra Paediatric Hospital (CPH) is part of the Coimbra Hospital and University Centre (CHUC), the largest hospital centre in Portugal. Known for its integrated research, teaching and patient care approach, and founded within one of the oldest universities in the world, CPH provides a range of specialist paediatric services to local, national and international patients and will commemorate its 40th anniversary this year. Since its formation, the hospital has been dedicated to comprehensive children’s healthcare, aiming to provide world-class clinical care and professional training whilst pioneering new research and treatments in partnership with others for the benefit of children worldwide.

CHUC’s Medical Genetics Unit is the largest clinical genetics department in the country, attending to both child and adult populations, and is deeply committed to improving genetics at the national level and within international networks. It is the only Iberian member of the European Reference Network (ERN) on Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA) and of the ERN on Rare Bone Disorders (ERN-BOND). For further inquiries contact: Sérgio B. Sousa, sbsousa@chuc.min-saude.pt.

About Coimbra Genomics

Coimbra Genomics, S.A. is a Digital Health and Precision Medicine start-up, headquartered in Cantanhede, Portugal. Coimbra Genomics has developed and is commercializing ELSIE, a first-in-class digital platform that allows physicians of any speciality to use information on their patient’s genome during regular medical appointments in an easy, fast and secure way, to make individualized decisions about diagnosis or prognosis. Coimbra Genomics has been voted one of the Top 3 Promises in Europe in the field of Digital Health. For further inquiries, please contact: Sónia Martins, info@coimbra-genomics.com.

About Genoinseq by Biocant

Genoinseq is the Next Generation Sequencing Unit of Biocant, at Cantanhede, Portugal. This unit grants access to the full potential of next generation sequencing equipment and bioinformatics data analysis for delivery of personalized solutions. In operation since 2007, Genoinseq provides services to companies and research groups in the field of Life Sciences and collaborates in R&D projects. For further inquiries, please contact: Conceição Egas, genoinseq@biocant.pt.

About Congenica

Congenica is a leading global provider of clinical genetics software and services. Headquartered in Cambridge UK, the company was founded on pioneering research from the Sanger Institute based at the Wellcome Genome Campus. We help clinicians and scientists rapidly and accurately diagnose patients with inherited genetic diseases with our clinical genomic analytics platform, Sapientia®. The platform provides a secure cloud-based software which enables analysis and interpretation of genetic data, linked to a patients’ phenotype which helps clinicians and scientists rapidly and accurately diagnose patients with inherited genetic diseases, accelerating access to the best treatment and prevention strategies. Sapientia is used by hospitals, clinics, research institutions and consortia, biotech, and pharma worldwide including Genomics England and leading genetic diagnosis centres in the National Health Service (NHS).
 

About Sapientia™

Sapientia is a clinical genome analysis software platform that analyzes genome-scale DNA data to produce a comprehensive diagnostic report that can be linked to patients’ symptoms, supporting clinical decision-making about rare genetic disease. The platform is based on pioneering research from the UK’s Wellcome Trust Sanger Institute, NHS clinicians, and its underlying technology has been validated by leading independent institutes and clinicians, including Genomics England Ltd. Sapientia is also being used in the advancement of personalised medicine by the global pharmaceutical industry to create disease registries, identify patient populations for clinical studies, and support the discovery of novel drug targets and biomarkers.

Rare Revolution: Giving a voice to young people living with rare disease

Rare-Rev-2.png

Rare Revolution Magazine is unique. Dedicated to giving rare disease sufferers and their families a voice and building them a community. It could easily be mistaken for a corporate enterprise, but is, in fact, a home-grown non-profit borne out of small village in Aberdeenshire.

Created by two sisters, themselves members of a rare disease family, it is now one of the most vibrant and trusted portals for rare disease parties to come together in a safe, respectful and informed community.

With their efforts going from strength to strength, they were approached by the Wellcome Genome Campus in Cambridge to present their story to some of the leading minds in genomics when they addressed the October, ‘Bench to Boardroom’ lecture.

“It seems strange to hear ourselves referred to as entrepreneurs and to be here now talking to people who are experts in their fields. Maybe we have a bit of imposter syndrome? But therein lies the crux of what we’ll talk about today, it's the experience and knowledge of the patients themselves and those closest to them which is so often not fully utilised.”

Nicola Miller and Rebecca Stewart established the Teddington Trust charity in 2012, in the wake of Nicola’s son’s diagnosis with Xeroderma Pigmentosum (XP) as a way of both communicating the condition to her son and raising awareness for others around them.

The condition is an autosomal recessive disorder, in which cells lack the ability to repair the damage caused by ultraviolet (UV) light. This can lead to sufferers developing multiple basal cell carcinomas and other dangerous skin malignancies that commonly affect the patient at a young age, forming metastatic malignant melanoma and squamous cell carcinoma - sadly, the most common causes of death amongst those afflicted.

Little Ted is the star of the Teddington Trust books and stories, which focus on educating those affected by the condition and normalising it for children struggling with it. Nicola’s Little Ted books have won a British Medical Association award for their accessible, well designed and clinically balanced patient relevant information.

The two sisters went on to launch their magazine, Rare Revolution, in the Autumn of 2016. “We were motivated to start the magazine because we had a hit a few hurdles in communicating through the charity,” said Rebecca Stewart. “It's difficult, with such personal stories about such rare conditions, to stop them becoming a ‘woe is me’ human interest story. We had received interest from the mainstream press before but it was harnessed in a negative light.

“At first we imagined a glorified newsletter. We initially built it up from the community on our Facebook page to create a multi-stakeholder environment.” Said Rebecca Stewart. “That community was one of the most unexpected things about this, but has now become one of the most powerful. We received one video message from a reader about how it had affected him and it was such a raw message. We knew then that we were on the right track.”

The success they had seen, both in the magazine itself and the surrounding community, inspired them to start planning for the first edition of the magazine focused specifically on the experiences of children and young people. These groups, tragically, make up half of the world’s rare disease sufferers. They decided to call it the Rare Youth Project.

“We started working on the a version of the magazine that was not only focused on children with rare disease, but also planned, researched and written by children with rare diseases.” Said Rebecca.

“The kids have chosen their jobs and have set the editorial direction,” said Nicola Miller. “They have chosen the interviews, and not soft topics, but big issues and big names. They’ve interviewed people like Scottish First Minister, Nicola Sturgeon. They wanted to do assignments and have meetings, not just to do everything over Skype.”

This version of the magazine will not only be online but will see a print run too as they want to give the children something tangible to be proud of and to enable them to put copies in children’s hospitals and pediatricians thus bringing more people into their community fold. The publication date will be 25th February 2018.

Rebecca Stewart added: “They are really passionate and they want to be heard. They want to have ownership of their voices and of their conditions. Sadly, people often underestimate children’s views.”

The two sisters have no science or publishing backgrounds and have five children between them, run a charity, publish a magazine, write all the content, do all the graphics and layout, do all of the outreach and logistics themselves.

“We didn’t have a business plan when we started it, neither the charity nor the magazine,” stated Nicola Miller, “we just ploughed in, bought a domain and built a website. We do everything, what you see here (gesturing to herself and her sister) is the entirety of both businesses, we’re it.”

“Moving forward, we have to work smarter. We take on a lot and we work very hard but we have very little choice. We are entirely self funded and we will always be a not for profit organisation. Its very important as our community can’t feel safe if they fear we are a corporate entity that may co-opt their story.” Explained Rebecca Stewart.

“We would be a very bad prospect for investors because we are not going to change and they are not going to make their money back. We’d love to bring people on board but it's hard to find people willing to work so hard for no money.”

“When our children were born we both decided to be stay at home mums. Stay at home mums do the most important job in the world but society doesn't always recognise that. Said Rebecca. “What people need to realise is that mums, parents, patients, they are the real experts. They have to become experts, and fast, because their life or their children’s lives depend on it.”

You can show your support for those living with rare disease by subscribing for your free quarterly digital edition of the fantastic Rare Revolution magazine at www.rarerevolutionmagazine.com.

 

Welcome to HomeGrownYouth!!

HomeGrown is a community urban arts project based in Bristol, we aim to raise the profile of local graffiti artists and their art. This has been set up to encourage members of the community to interact with each and think about graffiti as an art form, which, can make the area you live a more interesting and colourful place. “We encourage the community’s artists, residents and local business owners to come together and create ideas to beautify and, in a way, possess their environment“. 

The weekend of the 11th and 12th of November 2006 saw the launch of HomeGrownYouth. Over 20 of Bristol finest and up and coming graffiti artists gathered at a site in Easton, Bristol, to take part in the first event. Artists spent the weekend painting boarding which surrounds the site on the corner of Goodhind Street and Pennywell Road, creating a free, open art exhibition. 

Communities all over the world, for thousands of years have decorated their immediate environment allowing them to both beautify it and to make it their own. But today the only decoration our streets can get legally are glossy advertisements and there are thousands of them. Graffiti is forced to be a crime and thus people treat it as such on both sides. The project works to break down misconceptions about the art form and to give it a positive role in the community. 

Project co-ordinator Becca Vagg, who lives in Bristol has been inspired by graffiti art for a long time, she felt frustrated at the negative attitude which was targeted at the graffiti community in Bristol, including her boyfriend who is a graffiti artist. 'In my local area of St Werburghs and St Paul’s there is a huge problem with tagging, which to me is not an art form. Many people regard tagging as the same as graffiti and there is a lot of negative attitude towards it. There are so many talented artists in the area and I wanted to set up a project to not only provide legal spaces to paint but to also raise the profile of the art and artists.' 

The project aims to work with building sites, shops, local businesses and home owners, to provide legal space for artists to paint on, replacing vandalized areas with works of art, which will not only benefit business and home owners but the local community. 


We hope to expand the project by securing funding and working in other areas of Bristol. We also hope to get young people involved by organising graffiti workshops, where they will learn graffiti skills and also have space for them to practice and display their work. 


the project will help young people by giving them the opportunity to express themselves in a creative way, build new skills, develop social interaction skills, learn from positive hole models as well as having a sense of achievement and pride on the community. it will also allow them to enter into the wider community with skills that will make them more employable. 

Copyright 2006 

Green Gems and Hidden Histories - A walk in Camden.

How to use this guide

This guide can be used either as a walk, followed from the instructions provided, or simply as a guide to interesting sights and activities around this fascinating and historical area.

The walk is less than a mile and takes about an hour to walk and takes in historic squares and views protected by Parliament for hundreds of years along with vibrant evidence of the area’s industrial heritage of railways and canals.

There is also a list of other places in the area to visit illustrating the area’s multifaceted and diverse histories, influences and expressions.

Regents Park Road Bridge

The walk begins on Regent’s Park Bridge where the new mural ‘Isokon Dreams’ is situated.

This bridge sits at what has always been a symbolic point in the area. To the east first industry and railways and now shops and bars, and to the west the affluent Georgian and Victorian terraces and to the south the Royal Parks.

The first bridge on the site was a three brick arches, with one crossing the tracks, but as the area around Camden Lock and Stables Market grew it was pulled down in 1846 to accommodate more lines beneath it and then again 70 years later when the lines were electrified and yet more added the modern bridge was built.

If you were standing there a hundred years ago the view would be a little different. Looking south east towards the city centre there would be dozens of steam engines of all types shunting around the yards or steaming beneath the bridge towards the countryside. Huge sheds hundreds of feet long for the trains would have stood, one on the left where Morrisons now stands and one on the right by Gloucester Avenue, only the Roundhouse remains, and ahead, towards the canal, would have stood the two huge 133ft chimneys of the underground stationary engine house which pulled the early trains up the incline from Euston.

The view up Regents Park Road would have been almost identical to what you see now.

Adelaide Nature Reserve

With the new mural on your left walk down Bridge Approach and turn left onto Adelaide Road. Now walk along for 5 minutes until you come to the gate of the nature reserve on your left.

Adelaide Nature Reserve is a tiny piece of what the whole of Camden would have been at one point some 300 years ago, natural wild meadow. It was founded in 1984 by former actress Ursula Granville, who appeared in such famous shows as Upstairs Downstairs and Doctor Who, and contains wild grasses and plants which would have grown here and across the south east all those years ago.

The reserve is spread over 0.8 acres of land containing a number of rare plants and animals including the yellow meadow ant and the chafer beetle which hadn’t been seen in Britain since the 1950’s. There is also a pond where newts and frogs live.

The reserve also affords the best view of the portals of the Primrose Hill Tunnel.

Primrose Hill Tunnel Portals

The tunnel portals are best viewed from the nature reserve.

Primrose Hill Tunnel was the first railway tunnel to be built in London. What you see are the two eastern portals of the tunnel the nearest of which was constructed in 1837 by the London & Birmingham Railway and the famous public school Eton College, who then owned the land.

It was the College’s idea to have such grand ornamental entrances to the tunnel with its towers and lion’s heads and people would travel from miles around to see them and watch the trains steaming through.

Primrose Hill Summit

Turn left at the gate of the nature reserve and continue up Adelaide Road. Take the first left onto Primrose Hill Road. Within a couple of minutes you will see Primrose Hill, follow the path to the top.

Six views of St. Paul’s Cathedral were protected by an act of Parliament in 1842 and this view from the summit of Primrose Hill is one of them. From here you can see all of London laid out beneath you and in the distance as far as Selhurst near Croydon.

At the bottom of the hill is the distinctive black netting of London oo’s Snowdon Aviary and beyond that Regents Park which was once one of Henry VIII hunting grounds, or chases as they were called then.

The hill itself, view aside, has always been a common feature in popular culture. William Blake wrote a poem about it, H.G. Wells made it the site of a Martian base, it is where Pongo took his evening walks in 101 Dalmatians and has featured in songs written by Blur, Oasis and Red Hot Chilli Peppers amongst many others.

Chalcot Square

Facing London, take the path down the hill to the left toward The Queens pub and Regents Park Road. Walk up Regents Park Road and turn right onto Sharpleshall Street and follow it into Chalcot Square.

The streets around Primrose Hill have been and are home to many famous and influential people over the years from Gwen Stefani and Jude Law to Alan Bennett and Friedrich Engels and Sylvia Plath.

Two hundred years ago the whole area was a hive of construction. The railways and canals were expanding, homes and businesses were being constructed and the whole area was awash with hundreds of labourers, called navvies.

Prosperous Londoners were instantly drawn to the grand houses by the hill and in Chalcot Square stood a great inn called The Chalk Farm Tavern which boasted not only a dancefloor capable of holding 1,000 people but also a 36ft high bandstand know as the Chinese Orchestra.

Regent’s Canal

Walk along Chalcot Road and take the first left onto Fitzroy Road. Follow Fitzroy Road to the end and turn right onto Gloucester Avenue. Follow Gloucester Avenue until you come to the canal and go down the towpath.

Regent’s Canal was built between 1816 and 1820 to connect the Grand Union Canal in the west with the River Thames at Limehouse in the east. The canal became a vital transport route for goods in and out of London.

The canal’s broad towpaths, along which modern people cycle and stroll for pleasure, were places of labour in their heyday and would be busy with barges and their crews and horses which would pull their heavy loads along the canal. When a barge would reach a tunnel, of which the Regent’s Canal contains two very long ones, the workers would lie on their backs on top of the boat and use their feet against the tunnels walls and roof to push themselves along.

Camden Lock and Gilbey’s Yard

Follow the towpath until you see the Roving Bridge and climb to its middle for the best view of the lock. From here you can go one of two ways; either left through the arch you have just passed and into the market or cross the bridge and turn left at the road and follow it towards the overhead railway bridge.

The area around Camden Lock was the heart of all the industry and bustle which went on around here. The whole area which is covered by the market now was once covered in repair shops, engine sheds, offices, warehouses and repair depots. Goods poured in and out on the canals and tracks and the area is honeycombed with underground storage rooms, catacombs and tunnels.

Here relics from very different times rub shoulders. The huge Georgian Interchange building looms over the site and the old studio where Jim Henson filmed the Muppets and the controversial Gilgamesh building stands alongside the original cobbles and arches.

Another interesting fact is that the underground tunnels and storage areas were not just the domain of the workers but that there were horses working there as well. You can still see the entrances for them with their specially placed steps so that the four legged animals could climb them easily.

Just past the diagonal Roving Bridge is the lock itself which let the barges move from one part of the canal, where the water level was higher, to another and next to it the original lock-keeper’s cottage which dates back to 1816. The lock-keeper would have stayed there all of the time to let the many barges through as they collected and delivered their goods.

Horse Hospital

If you are in the market make your way away from the canal and around the Gilgamesh building and follow the cobbled floor until you pass the Proud Gallery and the Horse Hospital is ahead of you. If you are on the road, continue under the bridge and go into the second large entrance the market, beneath the ‘Stables Market’ sign, and then turn right.

In the northern corner of Stables Market is a long, dark stone building. This was the horse hospital. At any time the site would have around 500 horses working around the area, pulling carriages and stock both above ground and below including the many animals working on the canal’s towpaths. They were hugely important to both the railways and waterways and this hospital is testament to that.

It was built in 1846 and the physical make-up of the area has changed little. These are still the same cobbles they walked on and the same walls that housed them.

An interesting fact about the site is that due to the extra earth built up to raise the street level to that of the railway, the outer walls of what is now the market and was then the train yard, had to be massively reinforced and here at the horse hospital they are almost 7ft thick.

Roundhouse

Walk back towards the market and turn left through the entrance with the ‘Stables Market’ sign above it and turn left up Chalk Farm Road toward Chalk Farm tube station until you reach the Roundhouse.

The roundhouse on most train depots were not remarkable, in fact, they were seldom actually round. This one on Chalk Farm Road though is an exception.

Train engines require a lot of space and track to turn around and this caused problems for which a creative solution needed to be found. Here we have a large round building with and open interior and an iron frame. The outer ring is split into 24 bays and in the middle is a huge turntable with railway lines on it. This meant that trains could come in and either park in one of the bays until needed or rest on the turntable which would then rotate and they were back out into the yard, facing the opposite way.

As steam power increased the engines became more sophisticated and by the time electric trains came into common use the Roundhouse had been redundant for almost a hundred years. All over the country they were being demolished but this one, built in 1846 and with its 160ft diameter survived but in a very different life to what it was designed for.

It became a live music venue and a very popular one in the 1960’s which hosted such enormous acts as The Rolling Stones, Pink Floyd and Jimi Hendrix. But this would not be enough to save it and in 1983 it closed again but reopened in 2004 as a centre for performing arts.

Some interesting sights nearby

Little Venice

Little Venice is an area of Regent’s Canal towards the Paddington Basin which is famous for its houseboats and elegant stucco terraces.

Its name was coined by the English poet Robert Browning. Its waterways are actually made up of a canal junction between Regent’s Canal and The Grand Union Canal.

Nearest tube Warwick Avenue or a 30-45 minute walk west along the towpath from Camden Lock.

The Jewish Museum

The Jewish Museum is housed in a Victorian listed building on Albert Street in Camden and has one of the Britain’s finest collections of ceremonial art alongside exhibitions recounting Jewish life in England and Camden.

Open Monday to Thursday 10-4 and Sunday 10-5

Nearest tube Camden Town

London Zoo

London zoo, opened in 1828, is the world’s oldest scientific zoo. It was first opened to the public in 1847 and now houses 651 different species.

The zoo went on to have a series of firsts with the worlds first reptile house in 1849, the first aquarium in 1853, the first insect house in 1881, and the first children’s zoo in 1939.

A massive renovation programme is currently underway to replace the current enclosures with more natural environments for the animals of which a number have been completed including the gorilla enclosure.

Open Monday to Sunday 10-5.30

Nearest tubes Barker Street or Regent’s Park

St. Pancras Old Church

St. Pancras Old Church is one of the oldest sites of Christian worship in the country. Though early records are scarce there is documentary evidence suggests it has existed since 314AD.

The graveyard is grade 1 listed and contains the tombs of Bank of England architect John Soane and his wife. The Beatles did a photo shoot there from which the cover of Hey Jude was taken.

St. Pancras Old Church, St. Pancras Way.

Nearest tubes Mornington Crescent or Kings Cross St. Pancras

Isokon Building

The Isokon Building on Lawn Road in Hampstead was the key project of Isokon, a London based company founded to design and construct modernist houses and flats and the fittings and furniture for them, was finished in 1934.

The 29 flat block, which now refurbished to 25 flats, was built to cater for a new market of young professionals in the 1930’s and featured staff quarters, kitchens and a large garage.

A club, The Isobar, opened there in 1937 and famous residents and regulars included Agatha Christie, Henry Moore, Barbara Hepworth and Walter Gropius, former head of the Bauhaus.

It is grade 1 listed and despite falling into dereliction in the 1990’s it is now mostly occupied by key workers and contains a public gallery space recreating the original interiors.

Nearest tube Belsize Park

Copyright 2007

C4D

1: - Home

The business world is changing. There is a new age coming and there will be a new type of professional at the forefront. Most evident of this shift is the need to bring together the disciplines of design and engineering. Through this collaboration new, innovative and world changing products services and systems will be developed.

The Centre for Competitive Creative Design, C4D, brings together two of the world’s leading academic establishments to develop this next generation of creative, design literate engineers, scientists, managers and designers.

Industry craves greater creativity and innovation through the partnership between The University of the Arts London (UAL) and Cranfield University C4D will utilise its unique position to seriously approach this integration of disciplines and different industry sectors.

The partnership will develop a novel and exciting education programme, an industry service, an incubation support function and research into competitive creative design. The Masters in design (MDes) will be the first example of this new approach, a postgraduate degree designed for a different world.

At C4D, we believe that engineering is creative, that creativity should be seen at all ends of the industry and that creativity is the key to unlocking the solutions to many of today’s problems.

About Us: -

The aim of C4D is to become a ‘hot-house’ that will become widely influential and distil creativity and innovation into the leadership of industry. Through education, research and consultancy that brings designers, scientists, engineers and managers together in a multi-disciplinary and culturally diverse, interactive environment.

We have seen that the world of commerce and business is changing and C4D is acting to address the demands of the future. The ‘global village’ means that in today’s business world operations which would have traditionally taken place in the same environment are now spread across the world. The very role of Western business is changing. There will be positions in industry which have been established for years which will not exist in the future.

Because we recognise these facts we also recognise that a new attitude and more importantly a new kind of professional are needed to fill new roles and rise to new challenges.

Essentially, the mission is this: “Change the way that enterprises innovate by driving creative design capability into the heart of their processes.”

The two educational establishments behind C4D are world leading specialist establishments. UAL is one of Europe’s leading creative educational establishments and has a strong track record in working at the interface between academic, creative design and commercial and industry enterprises. Meanwhile Cranfield is a world leader in post-graduate education and has extensive experience of undertaking innovative research and education programmes and offering consultancy services to a wide range of industry sectors. C4D will bring them together in a whole which is much more than their constitutive parts.

C4D will work with enterprises of all sizes and from all sectors of the industry from local businesses to blue chip companies. Through research, knowledge and by developing pragmatic frameworks that exploit creative design, C4D will give engineering, science and business professionals the tools to be able to better exploit the creative potential of the design process to solve problems at any level.

Enterprise & Industry: -

Innovation, design and creativity are the key factors underpinning competitiveness. If businesses are to successfully integrate these factors into their organisations then a clear understanding of the strategies, processes, tools and methods are critical.

C4D will provide these services to enterprises of all scales and from all sectors. But, what makes C4D unique is that we combine disciplines that integrate academic knowledge drawn from design, management and manufacturing with an understanding of professional practice made available to us through our extensive collaborations with industry of various specialised areas.

C4D are actively in the process of delivering a range of educational and consultative packages. This range covers the whole spectrum of business and industry and includes but is by no means limited to:

• Executive networks targeted at senior management level focusing on the key issues of use and integration of design capability to increase organisational performance.

• Professional workshops and senior management ‘master-classes’ delivered at both of C4D’s sites.

• Special initiatives to engage small and medium size enterprises and to promote a further understanding of the business and competitive potential of creative design practices.

• ‘Stepping stone’ academic research which would offer participating companies a direct route to C4D’s resources and researchers.

As a two centre enterprise, C4D can offer a great amount of resources to their collaborators. We have both the London based creative resources of UAL alongside the management and technological resources of Cranfield, where C4D’s operational centre is based.

The creative environment cultivated by C4D will embody the key characteristics of a design agency but with the unique atmosphere and understanding which leaves engineers and managers equally as at home as their creative counterparts. The MDes students also provide an energy, interest and perspective which can not be matched by any other industry centre.

We firmly believe that here at C4D we are setting out a blueprint of how creative and industry hubs will operate and connect in the future.

But C4D isn’t just providing opportunities and support for established businesses and industry sectors, we also have extensive support networks for creative enterprises and start-ups.

Once again C4D’s dual establishment base means that those wishing to pursue creative business careers can benefit from not just the intellectual property advice and support of UAL’s Ownit Initiative (www.own-it.org) and the Enterprise Centre for the Creative Arts (www.ecca-london.org) but also the Cranfield University Business Incubator Centre (CUBIC). CUBIC (www.cubic.org.uk) itself is funded through a £1million grant from the East of England Development Agency which provides cutting edge facilities and equipment and a vast range of business services and preferential use of Cranfield’s Innovation Centre.

Education:-

The Masters of Design, Innovation and Creativity in Industry is the crux of C4D. It is this course which utilises the fantastic resources which have been provided by UAL and Cranfield, both in an educational sense and also in a supportive sense, which will develop the next generation of industry leaders.

The course runs for one year as a full time undertaking or up to three years part time. It combines the three most crucial threads of C4D’s aims. That is, creativity, science and technology. Students will learn across disciplines and will have opportunities to work with leading industrial companies and leading design agencies across the business environment.

The course comprises three central phases, a teaching phase, a group project and an individual thesis. During each of these phases, students will tackle modules covering the creative aspects of design, strategy and branding on one hand and practical technology and manufacturing and relevant branches of management.

The modules which will be studied are as follows:

Creative modules:

• Creative design practice.

• Intergrated strategy, communication and branding.

• Customer lifestyle requirement engineering.

Applied science modules:

• Use of Novel materials and manufacturing techniques.

• Concept evaluation and prototyping.

Management school modules:

• Innovation and technology management.

• Programme and project management.

Elective modules:

• Creative design management and leadership.

• Creative enterprise and entrepreneurship.

• Design innovation for sustainability.

Though the course will run from Cranfield, the students will still benefit from the resources and support of both of the universities and though they are significantly different they also compliment each other very well and through this help to offer something even more unique to C4D.

UAL is Europe’s largest centre for education in art, design fashion and communication. It comprises many of London’s leading arts establishments including Central St. Martin’s and Chelsea College of Art alongside London College of Communication which has more than 100 years of creative media tradition and has produced such notable alumni as Charles Saatchi, Anish Kapoor, Terence Conran and James Dyson amongst many others.

Cranfield, on the other hand, specialises in post-graduate education often focusing on research. Based in pleasant, rural, surroundings Cranfield can even boast to be the only university in the UK with its own airfield. The university is one of the world leaders in research fields and was ranked last year as 11th best in the world by the Economist in 2007.

Peers: -

No copy provided.

Research: -

One of C4D’s key goals is to further expand its scope as a world leading research base. Cranfield already has a long history for practical engineering research and development but one aspect C4D will bring to the table is the artistic and creative influences of UAL.

Using creativity to drive competition and influence wealth creation is central to the C4D philosophy and already research themes are being developed to look at everything from building digital brand platforms to collaborative innovation enabled by design-centric pedagogy.

It will be this mix of creative and practical research across all aspects of business which will allow C4D to break new ground and drive industry and individuals to new levels and new goals.

Our Industrial Collaborators:-

Both UAL and Cranfield have wide reaching and long standing ties with various industries, institutions and corporate interests.

Cranfield itself as established itself on the corporate landscape to such a degree that a number of multi-national organisations and start-up companies have gone as far as locating offices and bases at the university’s site.

Here they benefit from the development and research services already available at Cranfield and under C4D they will also, further, benefit from the creative influence of UAL and the competitive surge provided by the sector leading students taking part in the MDes.

Some of the companies and concerns based there include Nissan, who design and develop vehicles there for the European market, Trafficmaster, who operate their European headquarters from the site and Io Systems who supply warehouse management systems to clients in the UK, Europe and the USA. The Nissan commitment alone represents an investment of £46 million.

All of these links and the simple proximity of highly established global brands and businesses are a huge boon to both the universities involved in C4D as well as the many small scale enterprises which operate from Cranfield’s Innovation Centre and have access to the rapid prototyping facility.

The services provided here by C4D centre around the concept of enabling these business and other industry sectors developing and exploiting creative design and using it to increase competitiveness and innovation. Spread across consultative support and vocationally based short courses that are capable of delivering creative design knowledge at an organisational, team and individual level.

UAL’s strongest industry links and collaborations centre around the many, extremely, high profile alumni who now hold many of the highest level positions in the world’s creative industries ranging from advertising to fashion design.

Students and staff at UAL regularly achieve recognition through a wide variety of pries and awards including The Saatchi Scholarship, British Fashion Designer of the Year and even the Turner Prize. The university as a whole was recognised in 2006 as ‘the UK’s best modern university’ by the Sunday Times University Guide.

To further expand on this philosophy of collaboration and innovation, C4D have initiated a forum to allow the three stakeholder communities; Cranfield, UAL and industry as a whole. The forum provides and environment where industry, academics and creative elements can exchange ideas, communicate and challenge research outputs and drive innovative research initiatives.

The Team:-

Ian Ferris –

Ian Ferris comes from a background as a design and innovation consultant. He has worked across a wide array of sectors and is currently a design associate for the Design Council’s Designing Demand scheme.

Currently Ian is involved in research into the development and exploitation of creative design capability in the servitisation process in manufacturing enterprises which is being funded by Cranfield’s Innovative Manufacturing Research Centre.

Prof. Rajkumar Roy –

Professor Roy is leading the competitive design research currently taking place at Cranfield and has been heavily involved in numerous aspects of industrial research for a number of years including; understanding creativity and innovation in virtual environments, improving enterprise creativity at individual, project and organisational levels, concept evaluation and structured innovation.

 

Copyright 2008